Literature DB >> 17212734

IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A.

J G Kadar1, J Schuster, N Hunzelmann.   

Abstract

We report a 51-year-old patient with severe haemophilia A developing a severe life-threatening anaphylactic reaction to recombinant factor VIII (rFVIII). Anaphylactic reactions are a rare but well-known side effect of FVIII products. The nature of these reactions could not be clarified as previous studies failed to demonstrate a specific IgE response. Here, we could prove a grade 3 anaphlyactic reaction as an IgE-mediated response to rFVIII for the first time by Western blotting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17212734     DOI: 10.1111/j.1365-2516.2006.01339.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

1.  Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.

Authors:  Dheeraj Verma; Babak Moghimi; Paul A LoDuca; Harminder D Singh; Brad E Hoffman; Roland W Herzog; Henry Daniell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

2.  Anaphylaxis after treatment with recombinant factor VIII: investigation and therapeutic challenge.

Authors:  Sofia Pires; Teresa Sevivas; Carla Chaves Loureiro; Borja Bartholomé
Journal:  BMJ Case Rep       Date:  2018-12-14

3.  Successful Desensitization of a Patient with Possible IgE-Mediated Anaphylactic Reaction to FVIII/VWF Concentrate.

Authors:  Burcin Beken; Velat Celik; Pinar Gokmirza Ozdemir; Tuba Eren; Mehtap Yazicioglu
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-06-17       Impact factor: 1.349

Review 4.  A cellular viewpoint of anti-FVIII immune response in hemophilia A.

Authors:  Sebastien André; Yann Meslier; Jordan D Dimitrov; Yohann Repessé; Srinivas V Kaveri; Sebastien Lacroix-Desmazes; Suryasarathi Dasgupta
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.